Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04825678 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine
A Phase 4 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 4
- Development phase
- 240
- Enrollment target
NCT04825678: Completed Phase 4 study, sponsored by Amgen.
NCT04825678 is a Phase 4 study that has completed, run by Amgen. The registered enrollment target is 240 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (54% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04825678, a Phase 4 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 240 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the effect of erenumab on medication-specific treatment satisfaction.
Primary Outcome
The TSQM version 1.4 is a 14-item instrument designed to measure important dimensions of participants' experiences with their medication. It has 4 domains: effectiveness, side effects, convenience, and overall satisfaction. Overall satisfaction scores could range from 0 to 100, with higher scores indicating greater satisfaction. A positive change from Baseline represents an increase in overall medication satisfaction. Worst postbaseline value observed up to erenumab discontinuation was used for
Interventions
- DRUG Erenumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2021-06-11 |
| Est. Completion | 2023-09-28 |
| Phase | Phase 4 |
What the finished NCT04825678 record still lists
NCT04825678 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (54% lower).
The record links to 0 conditions, and to 1 intervention - of which Erenumab is the first listed.
NCT04825678 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04825678 about?
NCT04825678 is a clinical study titled "A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine". The main purpose of this study is to evaluate the effect of erenumab on medication-specific treatment satisfaction.
What is the current status of trial NCT04825678?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 240 participants. The study started on 2021-06-11. Estimated completion is 2023-09-28.
What interventions are being tested in trial NCT04825678?
The interventions under investigation include: Erenumab (DRUG).
Who is sponsoring clinical trial NCT04825678?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04825678's enrollment target sits among peer trials
240 360th of 2000 higher than 1,635 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI